This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

PharMerica Provides Preliminary 2014 Guidance

Stocks in this article: PMC

PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, and oncology pharmacy services, today reaffirmed the full year 2013 guidance provided on November 5, 2013 and announced preliminary full year 2014 guidance.

For the full year 2014, the Company preliminarily expects:

  • Revenue in the range of $1.67 billion to $1.72 billion
  • Adjusted diluted earnings per share in the range of $1.35 to $1.50 1

The Company notes that its preliminary 2014 guidance reflects the impact of the Company’s recently announced investment in Onco360 but does not include the effect of any potential 2014 acquisition activity. PharMerica is targeting acquisitions that generate at least $100 million of annualized sales, in the aggregate, in each of 2014 and 2015.

Greg Weishar, PharMerica Corporation’s Chief Executive Officer, said, “2013 was a strong year for PharMerica, and we expect the organic bed growth to continue in 2014. Fiscal 2014 will be a transitional year for the Company, with significant potential upside in 2015 to come from accretive external growth opportunities. We are confident that our 2015 financial performance will be in line with or better than the Company’s 2013 financial results due to the strong tailwinds and anticipated acquisitions. We look forward to delivering strong financial performance and shareholder value in 2015 and beyond.”

PharMerica believes a number of factors position the Company to build an even stronger growth profile and create meaningful value for shareholders:

  • Significant opportunity for acquisitions;
  • Strategic investment in Onco360 to expand PharMerica’s presence in the rapidly growing oncology market;
  • Partnership with Innovatix to advance PharMerica’s position in the home infusion and specialty market;
  • Favorable demographic trends including an aging population;
  • Improving sales productivity;
  • Increasing number of brand-to-generic conversions;
  • Strong brand drug price inflation;
  • Lower cost of goods driven by increasing volumes of generic purchased directly from manufacturers;
  • Other supply chain initiatives that drive savings; and
  • Continued growth of Amerita and the specialty home infusion segment.

PharMerica also today provided an update on its ongoing restructuring efforts. The Company has taken steps to right size its cost structure and will continue to adjust its workforce and facility plans to reflect anticipated business needs.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs